CRISPR Therapeutics CRSP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$122.93M+5.9% | -$130.61M-22.7% | -$106.44M+49.0% | -$208.55M-53.3% | -$136M-264% | ||
| $4.32M-23.7% | $5.66M+27.7% | $4.43M-4.6% | $4.65M-1.8% | $4.74M-2.2% | ||
| $16.32M-9.7% | $18.08M+8.9% | $16.6M-5.7% | $17.61M-12.9% | $20.21M-7.9% | ||
| $0— | —— | —— | —— | -$25M— | ||
| -$13.02M-394% | $4.42M-63.7% | $12.18M— | —— | $43M+648% | ||
| $247K+106% | -$3.85M-1,717% | -$212K-328% | $93K-85.3% | $634K+460% | ||
| -$199K-101% | $13.55M— | —— | —— | -$10.54M-206% | ||
| -$8.8M-206% | $8.31M-18.0% | $10.14M+38.4% | $7.33M+425% | -$2.25M-115% | ||
| -$427K— | —— | -$834K+6.5% | -$892K-8.3% | -$824K-29.2% | ||
| -$108.9M-17.7% | -$92.55M-9.4% | -$84.63M+25.7% | -$113.88M-111% | -$53.95M-7.8% | ||
| $504K-2.5% | $517K+599% | $74K-36.8% | $117K-43.2% | $206K-18.9% | ||
| —— | $175.5K0.0% | $175.5K0.0% | $175.5K0.0% | $175.5K— | ||
| $4.62M— | —— | —— | $4.7M-6.0% | $5M+78.7% | ||
| -$410.74M— | —— | -$119.23M-270% | $69.98M+454% | -$19.76M— | ||
| -$722K-101% | $111.49M-59.9% | $278.11M— | $0-100% | $8.52M-43.1% | ||
| $13.53M— | —— | —— | —— | $0— | ||
| $591.91M+408% | $116.41M-60.8% | $296.77M+13,043% | $2.26M-78.7% | $10.59M-37.3% | ||
| -$32K-3,300% | $1K— | —— | $80K+95.1% | $41K+147% | ||
| $72.24M+18.3% | $61.06M-34.3% | $92.88M+323% | -$41.57M+34.1% | -$63.07M— | ||
| —— | —— | —— | —— | —— | ||
| -$1.52M-13.3% | -$1.34M+7.1% | -$1.45M-13.9% | -$1.27M-10.3% | -$1.15M-12.1% | ||
| $247K+106% | -$3.85M-1,717% | -$212K-328% | $93K-85.3% | $634K+460% | ||
| -$8.8M-206% | $8.31M-18.0% | $10.14M+38.4% | $7.33M+425% | -$2.25M-115% | ||
| $4.62M— | —— | —— | $4.7M-6.0% | $5M+78.7% | ||
| —— | $175.5K0.0% | $175.5K0.0% | $175.5K0.0% | $175.5K— | ||
| $13.53M— | —— | —— | —— | $0— | ||
| $6.16M+25.1% | $4.92M-73.6% | $18.66M+718% | $2.28M+10.0% | $2.07M+8.1% | ||
| -$32K-3,300% | $1K— | —— | $80K+95.1% | $41K+147% | ||
| $4.14M— | —— | $2.78M+309% | $680K-78.9% | $3.22M— | ||
| $1.12M— | —— | —— | —— | $0— | ||
| $600M— | —— | —— | —— | $0— | ||
| -$109.4M-17.5% | -$93.07M-9.9% | -$84.71M+25.7% | -$114M-111% | -$54.15M-7.7% | ||
| -$109.4M-17.5% | -$93.07M-9.9% | -$84.71M+25.7% | -$114M-111% | -$54.15M-7.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CRISPR Therapeutics generate?
- CRISPR Therapeutics (CRSP) generated -$400.0M in operating cash flow over the trailing twelve months.
- What is CRISPR Therapeutics's free cash flow?
- After $1.2M of capital expenditures, CRISPR Therapeutics's free cash flow was -$401.2M over the trailing twelve months, down 30.3% year over year.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
